OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

RECORDATI ORD/  IT0003828271  /

Euronext Milan
23/05/2024  11:08:44 Chg. -0.280 Volume Bid11:09:00 Ask11:10:00 Market Capitalization Dividend Y. P/E Ratio
48.880EUR -0.57% 39,387
Turnover: 1.92 mill.		 48.860Bid Size: 208 48.880Ask Size: 11 10.04 bill.EUR 2.46% 25.74
GlobeNewswire 23/03/2021 RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S AN...
GlobeNewswire 22/02/2021 RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBI...
GlobeNewswire 29/01/2021 RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
GlobeNewswire 30/11/2020 RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEA...
GlobeNewswire 29/10/2020 RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NE...
GlobeNewswire 01/10/2020 RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P....
GlobeNewswire 21/09/2020 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
GlobeNewswire 30/07/2020 RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET IN...
GlobeNewswire 17/06/2020 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S D...
GlobeNewswire 07/05/2020 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
GlobeNewswire 29/04/2020 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
GlobeNewswire 08/04/2020 Recordati Rare Diseases now holds Isturisa® European MA
GlobeNewswire 26/03/2020 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
GlobeNewswire 18/03/2020 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY D...
GlobeNewswire 18/03/2020 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). ...
GlobeNewswire 14/02/2020 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBIT...
GlobeNewswire 15/01/2020 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
GlobeNewswire 15/11/2019 RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)
GlobeNewswire 31/10/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING IN...
GlobeNewswire 23/10/2019 RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
GlobeNewswire 30/07/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
GlobeNewswire 12/07/2019 RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)
GlobeNewswire 24/06/2019 RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
GlobeNewswire 08/05/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED
GlobeNewswire 15/04/2019 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY